

Dr Carole Longson  
Centre for Health Technology Evaluation  
National Institute for Health and Clinical Excellence  
Level 1A City Tower  
Piccadilly Plaza  
Manchester  
M1 4BD

5<sup>th</sup> July 2009

Dear Dr Longson,

**Response to the Appraisal Consultation Document – Topotecan for the treatment of small-cell lung cancer**

This letter is a response, on behalf of the Roy Castle Lung Cancer Foundation.

We have no additional comment and are pleased to note the Appraisal Committee's decision, to recommend oral Topotecan for relapsed small cell lung cancer, for whom iv CAV treatment is contraindicated. This will allow patients, who currently do not access treatment in second line, to now do so.

If you require further information please contact us at the address above.

Yours sincerely,

